227 related articles for article (PubMed ID: 31351063)
41. Mechanistic basis of a combination D-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.
Chen SJ; Kuo CC; Pan HY; Tsou TC; Yeh SC; Chang JY
Biochem Pharmacol; 2015 May; 95(1):28-37. PubMed ID: 25801007
[TBL] [Abstract][Full Text] [Related]
42. Synergistic effects of pazopanib and hyperthermia against uterine leiomyosarcoma growth mediated by downregulation of histone acetyltransferase 1.
Lin CY; Chao A; Wu RC; Lee LY; Ueng SH; Tsai CL; Lee YS; Peng MT; Yang LY; Huang HJ; Wang HS; Lai CH
J Mol Med (Berl); 2020 Aug; 98(8):1175-1188. PubMed ID: 32638047
[TBL] [Abstract][Full Text] [Related]
43. ATPase Copper Transporting Beta (ATP7B) Is a Novel Target for Improving the Therapeutic Efficacy of Docetaxel by Disulfiram/Copper in Human Prostate Cancer.
Song L; Nguyen V; Xie J; Jia S; Chang CJ; Uchio E; Zi X
Mol Cancer Ther; 2024 Jun; 23(6):854-863. PubMed ID: 38417139
[TBL] [Abstract][Full Text] [Related]
44. Collateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells.
Doherty B; Lawlor D; Gillet JP; Gottesman M; O'Leary JJ; Stordal B
Anticancer Res; 2014 Jan; 34(1):503-7. PubMed ID: 24403508
[TBL] [Abstract][Full Text] [Related]
45. Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kanai Y; Shiozawa T; Tonegawa S; Konishi I
Protein Cell; 2010 Aug; 1(8):711-7. PubMed ID: 21203912
[TBL] [Abstract][Full Text] [Related]
46. Copper efflux transporters ATP7A and ATP7B: Novel biomarkers for platinum drug resistance and targets for therapy.
Li YQ; Yin JY; Liu ZQ; Li XP
IUBMB Life; 2018 Mar; 70(3):183-191. PubMed ID: 29394468
[TBL] [Abstract][Full Text] [Related]
47. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
48. Soft Tissue and Uterine Leiomyosarcoma.
George S; Serrano C; Hensley ML; Ray-Coquard I
J Clin Oncol; 2018 Jan; 36(2):144-150. PubMed ID: 29220301
[TBL] [Abstract][Full Text] [Related]
49. Role of copper transporters in resistance to platinating agents.
Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
[TBL] [Abstract][Full Text] [Related]
50. Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma.
Noh JJ; Cho YJ; Ryu JY; Choi JJ; Hwang JR; Choi JY; Lee JW
Clin Cancer Res; 2022 Sep; 28(17):3850-3861. PubMed ID: 35727598
[TBL] [Abstract][Full Text] [Related]
51. Imatinib is not a potential alternative treatment for uterine leiomyosarcoma.
Serrano C; Mackintosh C; Herrero D; Martins AS; de Alava E; Hernández T; Pérez-Fontán J; Abad M; Pérez A; Serrano E; Bullón A; Orfao A
Clin Cancer Res; 2005 Jul; 11(13):4977-9; author reply 4979-80. PubMed ID: 16000598
[No Abstract] [Full Text] [Related]
52. Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression.
Fu L; Zhang D; Yi N; Cao Y; Wei Y; Wang W; Li L
Hum Cell; 2022 Sep; 35(5):1560-1576. PubMed ID: 35907138
[TBL] [Abstract][Full Text] [Related]
53. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
54. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
O'Cearbhaill R; Zhou Q; Iasonos A; Soslow RA; Leitao MM; Aghajanian C; Hensley ML
Gynecol Oncol; 2010 Mar; 116(3):424-9. PubMed ID: 19932916
[TBL] [Abstract][Full Text] [Related]
55. Establishment of a cisplatin-induced multidrug resistance cell line SK-Hep1/DDP.
Zhou Y; Ling XL
Chin J Cancer; 2010 Feb; 29(2):167-71. PubMed ID: 20109345
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
57. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.
Samimi G; Varki NM; Wilczynski S; Safaei R; Alberts DS; Howell SB
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5853-9. PubMed ID: 14676106
[TBL] [Abstract][Full Text] [Related]
58. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.
Ravid Y; Formanski M; Smith Y; Reich R; Davidson B
Gynecol Oncol; 2016 Mar; 140(3):512-7. PubMed ID: 26768834
[TBL] [Abstract][Full Text] [Related]
59. Possible role of calponin h1 as a tumor suppressor in human uterine leiomyosarcoma.
Horiuchi A; Nikaido T; Taniguchi S; Fujii S
J Natl Cancer Inst; 1999 May; 91(9):790-6. PubMed ID: 10328110
[TBL] [Abstract][Full Text] [Related]
60. Cisplatin ototoxicity in rat cochlear organotypic cultures.
Ding D; He J; Allman BL; Yu D; Jiang H; Seigel GM; Salvi RJ
Hear Res; 2011 Dec; 282(1-2):196-203. PubMed ID: 21854840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
